MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Net Income
-$5,371,465
EPS
-$1.9
Unit: Dollar
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
General and administrative
1,846,406
1,697,448
1,265,891.5*
1,738,751
Research and development
3,627,168
3,433,762
3,305,628.25*
2,281,174
Total operating expenses
5,473,574
5,131,210
4,571,519.75*
4,019,925
Unrealized (loss) gain
1,585
-13,300
-1,255*
9,494
Realized and accrued interest income
100,947
146,775
233,814.5*
62,266
Total other income
102,532
133,475
232,559.5*
71,760
Net loss
-5,371,042
-4,997,735
-4,338,960.25*
-3,948,165
Foreign currency translation
-423
454
-153.25
-
Total other comprehensive loss
-
-
-153.25*
-
Comprehensive loss
-5,371,465
-4,997,281
-4,339,113.5
-
Basic EPS
-1.9
-1.77
-2.803
-6.71
Diluted EPS
-1.9
-1.77
-2.803
-6.71
Basic Average Shares
2,832,915
2,830,970
1,548,138
588,166
Diluted Average Shares
2,832,915
2,830,970
1,548,138
588,166
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Comprehensive loss
-$5,371,465
Realized and accrued
interest income
$100,947
(-2.23%↓ Y/Y)
Unrealized (loss) gain
$1,585
(126.40%↑ Y/Y)
Net loss
-$5,371,042
(-45.32%↓ Y/Y)
Foreign currency
translation
-$423
Total other income
$102,532
(5.44%↑ Y/Y)
Total operating
expenses
$5,473,574
(44.30%↑ Y/Y)
Research and development
$3,627,168
(76.88%↑ Y/Y)
General and
administrative
$1,846,406
(5.96%↑ Y/Y)
Buy us a coffee
Quoin Pharmaceuticals, Ltd. (QNRX)
Quoin Pharmaceuticals, Ltd. (QNRX)